KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EPS (Basic): 2009-2024

Historic EPS (Basic) for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $1.37.

  • Acadia Pharmaceuticals' EPS (Basic) rose 115.00% to $0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.57, marking a year-over-year increase of 101.28%. This contributed to the annual value of $1.37 for FY2024, which is 470.27% up from last year.
  • Acadia Pharmaceuticals' EPS (Basic) amounted to $1.37 in FY2024, which was up 470.27% from -$0.37 recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year EPS (Basic) high stood at $1.37 for FY2024, and its period low was -$1.79 during FY2020.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.37 (2023), whereas its average is -$0.11.
  • Its EPS (Basic) has fluctuated over the past 5 years, first fell by 27.62% in 2022, then surged by 470.27% in 2024.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' EPS (Basic) stood at -$1.79 in 2020, then skyrocketed by 41.34% to -$1.05 in 2021, then declined by 27.62% to -$1.34 in 2022, then spiked by 72.39% to -$0.37 in 2023, then surged by 470.27% to $1.37 in 2024.